(NewsDirect)
Willow Bioscience CEO Dr Chris Savilejoined Steve Darling from Proactive to announce some significantdevelopments within the company.
Willow Bioscience specializes in the production ofursodeoxycholic acid (UDCA), a vital pharmaceutical ingredient withextensive applications in nutraceutical and pharmaceutical products.UDCA is notably used in the management and treatment of cholestaticliver diseases and gallstone conditions. Moreover, it serves as acrucial intermediate compound for tauroursodeoxycholic acid (TUDCA),an essential active pharmaceutical ingredient in a recently approvedcombination therapy for the treatment of ALS in Canada and the UnitedStates.
In partnership withSandhill One, LLC, Willow has successfully completed research anddevelopment on its UDCA program. This collaborative initiative enabledWillow to optimize a proprietary enzyme necessary for UDCAdevelopment. Of particular significance is the achievement ofselective C-H hydroxylation at an industrial scale, often regarded asa challenging feat in the field of chemistry.
Dr Savile's announcement alsoextended to the financial front. Willow Bioscience is initiating anoffering of convertible debenture units in a non-brokered privateplacement to raise approximately $1.2 million. Notably, insiders,including members of the Board of Directors and senior management, areexpected to subscribe to approximately 50% of the total funds raised.This underscores the strong commitment and confidence that thecompany's leadership has in Willow's vision and futureprospects.
These developments indicate that Willow Bioscienceis making significant strides in its mission to advance pharmaceuticalresearch and contribute to the development of innovative therapies andtreatment options. With a focus on expanding its product portfolio andsecuring essential funding, the company is poised to play a pivotalrole in the pharmaceutical and nutraceutical industries.
Contact Details
Proactive Investors
+1604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.